Dabrafenib and Lorlatinib

The combination of dabrafenib and lorlatinib represents a targeted therapy approach used in the treatment of certain types of non-small cell lung cancer (NSCLC). This combination has been specifically documented in the treatment of ROS1-rearranged advanced NSCLC with lorlatinib-induced BRAF mutations.\n\n## Mechanism and Clinical Application\n\nDabrafenib is a BRAF kinase inhibitor that targets cells with BRAF mutations, particularly the V600E mutation[1][3]. It works by blocking the actions of abnormal BRAF, inhibiting cell replication and potentially causing cancer cell death[6]. Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) inhibitor with activity against ALK and other tyrosine kinase receptors including ROS1[2].\n\nIn ROS1-rearranged NSCLC, patients may initially respond to ROS1 tyrosine kinase inhibitors like crizotinib, but resistance can develop. When patients subsequently receive lorlatinib treatment, a BRAF V600E mutation can emerge as a resistance mechanism[1]. The combination of lorlatinib with dabrafenib and trametinib (a MEK inhibitor) has been used to overcome this resistance pattern.\n\n## Clinical Evidence\n\nA case report documented a 31-year-old female patient with stage IVB ROS1-rearranged NSCLC who developed resistance to crizotinib (with an NF1 mutation) and subsequently to lorlatinib (with emergence of a BRAF V600E mutation). When treated with the combination of lorlatinib, dabrafenib, and trametinib, she achieved stable disease with a time-to-treatment failure of 5.5 months[1].\n\n## Drug Interactions\n\nThere are notable pharmacokinetic interactions between these medications. Dabrafenib can decrease the serum concentration of lorlatinib[2][5]. This is likely due to dabrafenib's effect as an inducer of metabolic enzymes, which can reduce exposure to lorlatinib.\n\n## Administration Considerations\n\nDabrafenib is taken orally in capsule form and should be taken on an empty stomach (1 hour before or 2 hours after eating). The capsules should not be opened, crushed, broken, or chewed[6]. Specific administration details for the combination therapy would be determined by the treating physician based on individual patient factors.\n\nThis combination represents an innovative approach to addressing resistance mechanisms in targeted cancer therapy, particularly for patients with ROS1-rearranged NSCLC who develop BRAF mutations during lorlatinib treatment.